NCT05900583View on ClinicalTrials.gov

Efficacy Evaluation and Recurrence Monitoring of Therapy for Esophageal Squamous Cell Carcinoma Based on ctDNA-MRD.

UnknownOBSERVATIONAL
Enrollment

50

Participants

Timeline

Start Date

June 1, 2023

Primary Completion Date

May 1, 2025

Study Completion Date

August 31, 2025

Conditions
Minimal Residual DiseaseEsophageal Squamous Cell Carcinoma
Trial Locations (1)

510080

Guangdong Provincial People's Hospital, Guangzhou

Sponsors

Collaborators (1)

Haplox
All Listed Sponsors
collaborator

Haplox

UNKNOWN

lead

Guangdong Provincial People's Hospital

OTHER